Alexandria Hammond
Stock Analyst at B of A Securities
(3.37)
# 996
Out of 5,090 analysts
16
Total ratings
70%
Success rate
13.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Upgrades: Neutral | $266 → $445 | $577.30 | -22.92% | 2 | Nov 3, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $63 → $64 | $54.55 | +17.32% | 4 | May 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $718.36 | +60.09% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $26.03 | -3.96% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $27.70 | +44.40% | 1 | Nov 15, 2024 | |
| MRK Merck & Co. | Initiates: Peer Perform | n/a | $99.72 | - | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $1,010.31 | -1.02% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $201.93 | -5.91% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $121.22 | -9.26% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $52.15 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $181.30 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $205 | $226.08 | -9.32% | 1 | Nov 15, 2024 |
Madrigal Pharmaceuticals
Nov 3, 2025
Upgrades: Neutral
Price Target: $266 → $445
Current: $577.30
Upside: -22.92%
Akero Therapeutics
May 27, 2025
Maintains: Buy
Price Target: $63 → $64
Current: $54.55
Upside: +17.32%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $718.36
Upside: +60.09%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $26.03
Upside: -3.96%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $27.70
Upside: +44.40%
Merck & Co.
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $99.72
Upside: -
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $1,010.31
Upside: -1.02%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $201.93
Upside: -5.91%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $121.22
Upside: -9.26%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $52.15
Upside: -
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $181.30
Upside: -
Nov 15, 2024
Initiates: Outperform
Price Target: $205
Current: $226.08
Upside: -9.32%